ACG unveils desiccant-based cold-form laminate for pharma products in India

ACG, the world’s most integrated provider of solid-dosage and packaging solutions, has announced the launch of DryPod™, a next-generation desiccant-based cold-form laminate engineered to protect highly moisture-sensitive drug molecules.

DryPod™ marks a major advancement for pharmaceutical manufacturers who have long grappled with limited availability, rigid technologies, and compatibility issues within existing desiccant cold-form solutions.

Moisture protection is essential to ensure drug potency throughout the product’s retail life. However, current market offerings rely heavily on a single patented co-extrusion-based technology, creating challenges such as restricted machine compatibility, dependence on specific lidding foils, long lead times, limited supplier options, and inconsistent on-ground technical support.

DryPod™ overcomes these barriers, giving pharmaceutical companies the freedom to innovate without compromising product protection, regulatory compliance, or operational efficiency.

Unlike legacy co-extruded structures, DryPod™ is built using a proprietary lamination-based approach, enabling consistent performance across all standard blister-forming technologies. This eliminates the need for specialised retrofits or process changes and gives manufacturers complete flexibility to run DryPod™ on their existing blister lines. The laminate can also be sealed with any PE-sealable lidding foil, reducing procurement dependencies and ensuring supply-chain agility across global operations.

A significant differentiator for DryPod™ is its patent-clean design. Engineered with zero overlap with existing active patents in the desiccant co-extrusion space, DryPod™ offers pharmaceutical companies complete legal clarity and peace of mind when switching suppliers, scaling production, or expanding into new markets.